Literature DB >> 20201627

Redirecting the immune response: role of adoptive T cell therapy.

Anna Mondino1, Valérie Dardalhon, Rodrigo Hess Michelini, Severine Loisel-Meyer, Naomi Taylor.   

Abstract

Adoptive T cell therapy is aimed at overcoming constraints of the endogenous immune response. In patients with malignancies, this approach is based on the possibility of administering sufficient numbers of tumor-reactive lymphocytes under conditions in which they will promote a therapeutic response. Although this strategy is potentially applicable to a vast number of malignancies, its efficacy, to date, has been limited. This is likely related to several factors including an insufficient persistence and reactivation of infused cells, insufficient tumor infiltration, and the presence of an immunosuppressive environment. Here, we review the importance of pretransplantation host conditioning and posttransplantation strategies that have been shown to contribute to the therapeutic efficacy of infused T lymphocytes.

Entities:  

Mesh:

Year:  2010        PMID: 20201627      PMCID: PMC2938351          DOI: 10.1089/hum.2010.033

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  102 in total

1.  Adoptive T-cell therapy for malignant disorders.

Authors:  Daniel J Powell; Bruce L Levine
Journal:  Haematologica       Date:  2008-10       Impact factor: 9.941

2.  Requirements for effective antitumor responses of TCR transduced T cells.

Authors:  Moniek A de Witte; Annelies Jorritsma; Andrew Kaiser; Marly D van den Boom; Maarten Dokter; Gavin M Bendle; John B A G Haanen; Ton N M Schumacher
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

3.  CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity.

Authors:  Thomas Calzascia; Marc Pellegrini; Albert Lin; Kristine M Garza; Alisha R Elford; Arda Shahinian; Pamela S Ohashi; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-14       Impact factor: 11.205

4.  Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.

Authors:  F Stephen Hodi; Marcus Butler; Darryl A Oble; Michael V Seiden; Frank G Haluska; Andrea Kruse; Suzanne Macrae; Marybeth Nelson; Christine Canning; Israel Lowy; Alan Korman; David Lautz; Sara Russell; Michael T Jaklitsch; Nikhil Ramaiya; Teresa C Chen; Donna Neuberg; James P Allison; Martin C Mihm; Glenn Dranoff
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

5.  Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.

Authors:  John A Thompson; Brendan D Curti; Bruce G Redman; Shailender Bhatia; Jeffrey S Weber; Sanjiv S Agarwala; Eric L Sievers; Steven D Hughes; Todd A DeVries; Diana F Hausman
Journal:  J Clin Oncol       Date:  2008-03-17       Impact factor: 44.544

6.  IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.

Authors:  Christian S Hinrichs; Rosanne Spolski; Chrystal M Paulos; Luca Gattinoni; Keith W Kerstann; Douglas C Palmer; Christopher A Klebanoff; Steven A Rosenberg; Warren J Leonard; Nicholas P Restifo
Journal:  Blood       Date:  2008-02-14       Impact factor: 22.113

7.  The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma.

Authors:  Eleanor J Cheadle; David E Gilham; Robert E Hawkins
Journal:  Br J Haematol       Date:  2008-05-08       Impact factor: 6.998

8.  IL-15 serves as a costimulator in determining the activity of autoreactive CD8 T cells in an experimental mouse model of graft-versus-host-like disease.

Authors:  Fumi Miyagawa; Yutaka Tagaya; Brian S Kim; Hiral J Patel; Kazuto Ishida; Toshiaki Ohteki; Thomas A Waldmann; Stephen I Katz
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

9.  Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma.

Authors:  Nobusada Koike; Shari Pilon-Thomas; James J Mulé
Journal:  J Immunother       Date:  2008-05       Impact factor: 4.456

10.  Interleukin-15 favors the expansion of central memory CD8+ T cells in ex vivo generated, antileukemia human cytotoxic T lymphocyte lines.

Authors:  Liane Daudt; Rita Maccario; Franco Locatelli; Ilaria Turin; Lucia Silla; Enrica Montini; Elena Percivalle; Roberto Giugliani; Maria Antonietta Avanzini; Antonia Moretta; Daniela Montagna
Journal:  J Immunother       Date:  2008-05       Impact factor: 4.456

View more
  3 in total

1.  Lactobacillus acidophilus could modulate the immune response against breast cancer in murine model.

Authors:  Hamidreza Maroof; Zuhir Mohammad Hassan; Ashraf Mohabati Mobarez; Maryam Azimi Mohamadabadi
Journal:  J Clin Immunol       Date:  2012-06-19       Impact factor: 8.317

2.  Expression of leukotriene B₄ receptor-1 on CD8⁺ T cells is required for their migration into tumors to elicit effective antitumor immunity.

Authors:  Rajesh Kumar Sharma; Zinal Chheda; Venkatakrishna Rao Jala; Bodduluri Haribabu
Journal:  J Immunol       Date:  2013-08-19       Impact factor: 5.422

3.  Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment.

Authors:  Hui-Yen Chuang; Ya-Fang Chang; Ren-Shyan Liu; Jeng-Jong Hwang
Journal:  PLoS One       Date:  2014-10-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.